Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)‘s stock had its “hold” rating reaffirmed by research analysts at Piper Jaffray Cos. in a report issued on Tuesday. They presently have a $447.00 target price on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s target price would indicate a potential upside of 10.96% from the company’s previous close.

Several other equities analysts have also issued reports on the company. Vetr lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $419.76 price objective on the stock. in a report on Monday, July 11th. Jefferies Group reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 17th. Chardan Capital lowered Regeneron Pharmaceuticals to a “sell” rating and set a $325.00 price objective on the stock. in a report on Wednesday, June 8th. Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.00 price objective on the stock in a report on Tuesday, August 9th. Finally, Roth Capital reaffirmed a “buy” rating and set a $520.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $470.91.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.85% during trading on Tuesday, reaching $406.24. The company had a trading volume of 624,782 shares. The firm has a 50-day moving average of $409.49 and a 200-day moving average of $389.48. The stock has a market capitalization of $42.51 billion, a price-to-earnings ratio of 63.38 and a beta of 1.24. Regeneron Pharmaceuticals has a 1-year low of $329.09 and a 1-year high of $592.59.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/regeneron-pharmaceuticals-inc-regn-given-hold-rating-at-piper-jaffray-cos.html

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.65 by $0.17. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.24 billion. During the same period last year, the firm earned $2.89 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 21.4% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals will post $10.93 EPS for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,125 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $425.00, for a total value of $903,125.00. Following the completion of the sale, the director now directly owns 15,125 shares of the company’s stock, valued at approximately $6,428,125. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.40% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. EQIS Capital Management boosted its stake in shares of Regeneron Pharmaceuticals by 49.5% in the fourth quarter. EQIS Capital Management now owns 5,032 shares of the biopharmaceutical company’s stock valued at $2,732,000 after buying an additional 1,666 shares in the last quarter. Reynolds Capital Management boosted its stake in shares of Regeneron Pharmaceuticals by 40.0% in the fourth quarter. Reynolds Capital Management now owns 2,100 shares of the biopharmaceutical company’s stock valued at $1,140,000 after buying an additional 600 shares in the last quarter. Banced Corp boosted its stake in shares of Regeneron Pharmaceuticals by 17.9% in the fourth quarter. Banced Corp now owns 1,358 shares of the biopharmaceutical company’s stock valued at $737,000 after buying an additional 206 shares in the last quarter. Janus Capital Management boosted its stake in shares of Regeneron Pharmaceuticals by 8.1% in the third quarter. Janus Capital Management now owns 2,150,037 shares of the biopharmaceutical company’s stock valued at $1,000,078,000 after buying an additional 160,589 shares in the last quarter. Finally, Braun Stacey Associates bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at about $9,070,000. 68.16% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.